Toronto, Ontario--(Newsfile Corp. - April 18, 2016) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm Solutions" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, today announced it has commenced a sales and marketing campaign through Kentucky-based Club Solutions Magazine for the sale of HeartCheck™ ECG devices and the use of the SMART Monitoring ECG reading services to wellness, health and sports clubs as well as personal trainer business in the USA and Canada. The Company also confirms they have been working with multiple device manufacturers to bring new HeartCheck™ branded ECG recording devices to market that will support Smartphone connectivity, are wearable and can be offered with pricing and functionality intended to be directly competitive with offerings such as Fitbit's fitness band, Medtronic's Corventis ECG patch and AliveCor's ECG card.
Disclosed through the April issue of the Club Solutions publication, the HeartCheck™ ECG Screening Partner Program is offered to health and sports club operations as an added value business offering to provide appropriate and medically relevant cardiac health screening for their customers. While the HeartCheck™ ECG Partner Program is currently supported through the use of the HeartCheck™ ECG PEN, the Company has been busy this past year developing new HeartCheck™ devices for use with their SMART Monitoring service such as a Bluetooth version of the HeartCheck™ ECG PEN, the HeartCheck™ Lifeband and two versions of a business card sized device to be named the HeartCheck™ ECG Card.
The multi-month campaign will be supported by Club Solutions through their website, press releases, social media promotion, opt in email subscribers and via print. The campaign will reach an anticipated 150,000 Club Solutions clients and subscribers internationally each month. The print edition of the Club Solutions Magazine will be distributed to 24,000 health club operators, the majority of which are located in the USA. Distribution will also specifically reach each of the 350 GoodLife Fitness clubs in Canada. The HeartCheck™ Partner Program and new HeartCheck™ device previews are in the new Fitness Tracking/Testing category section of the publication and will also be shown as a highlighted Fitness Technology product feature. The products will also be carried in the October buyer's guide for 2016/2017.
Health and sports club operators are actively searching for additional revenue opportunities and to be at the top of their game in providing new and advanced technologies to enhance the health and wellness experience of their members. With multijurisdictional clearances from medical organizations for consumer use of the HeartCheck™ devices and SMART Monitoring, expansion into this evolving market would offer a largely unchallenged market opportunity. Sports organizations looking to provide easy and meaningful health screening solutions that provide real and medically relevant reports for their members will benefit from having access to CardioComm Solutions' technologies which have a seventeen year track record of providing ECG monitoring solutions into traditional medical installations such as hospitals, physician offices and medical call centers. CardioComm Solutions' technologies hold clearances for the sale of HeartCheck™ technologies to consumers from the European Union (CE Mark), Australia (TGA), the USA (FDA), China (CFDA) and Canada (Health Canada).
Regular ECG screening has been shown to reduce the risk for sudden cardiac death and the parallel between offering screening in the setting of where people are involved in returning to or maintaining an active and health lifestyle is not lost on the health club industry. Additionally, offering a cardiac monitoring opportunity would add comfort where customers are experiencing any symptoms of dizziness or discomfort especially when associated with physical and emotional stress.
This announcement follows a recently reported initiative involving the introduction of the HeartCheck™ ECG Partner Program to US-based pharmacists. The Company confirms that similar projects are being planned for the USA, Canadian and European markets for community physicians, pharmacists, physiotherapists in sports clubs and gyms as well as workplace screening programs.
To learn more about the CardioComm Solutions' products, please see the Company's websites www.theheartcheck.com and www.cardiocommsolutions.com or contact the Company at sales@cardiocommsolutions.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada.
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x 227
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
copyright (c) newsfile corp. 2016